<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:06c14a77-05e4-4573-87af-e4326ea5e22c,g:13b1e340-ccd7-4782-beb8-fab81a2df124,d:fe3c953a95714ab997f02a386455ae24--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>eigr-20230511</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="iab1696d2ac69401598d18b7b33e087c3_D20230511-20230511" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmZlM2M5NTNhOTU3MTRhYjk5N2YwMmEzODY0NTVhZTI0L3NlYzpmZTNjOTUzYTk1NzE0YWI5OTdmMDJhMzg2NDU1YWUyNF80L2ZyYWc6NTExZjE1YzczZTVkNDJlN2IxODQ0ZjRkNDBjZDZjMjcvdGFibGU6NTYxNjEzN2ZiYmRmNGUwMDljNDIxMGRkOTc3ZjVjZDIvdGFibGVyYW5nZTo1NjE2MTM3ZmJiZGY0ZTAwOWM0MjEwZGQ5NzdmNWNkMl8wLTEtMS0xLTQ5Njc3_a67aa356-6b96-413e-b1fe-9d7bc70d2fea">false</ix:nonNumeric><ix:nonNumeric contextRef="iab1696d2ac69401598d18b7b33e087c3_D20230511-20230511" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmZlM2M5NTNhOTU3MTRhYjk5N2YwMmEzODY0NTVhZTI0L3NlYzpmZTNjOTUzYTk1NzE0YWI5OTdmMDJhMzg2NDU1YWUyNF80L2ZyYWc6NTExZjE1YzczZTVkNDJlN2IxODQ0ZjRkNDBjZDZjMjcvdGFibGU6NTYxNjEzN2ZiYmRmNGUwMDljNDIxMGRkOTc3ZjVjZDIvdGFibGVyYW5nZTo1NjE2MTM3ZmJiZGY0ZTAwOWM0MjEwZGQ5NzdmNWNkMl8xLTEtMS0xLTQ5Njc3_6d907871-7192-47a4-b7f3-97d362c22bd7">0001305253</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="eigr-20230511.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="iab1696d2ac69401598d18b7b33e087c3_D20230511-20230511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-11</xbrli:startDate><xbrli:endDate>2023-05-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ife3c953a95714ab997f02a386455ae24_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.08pt"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="iab1696d2ac69401598d18b7b33e087c3_D20230511-20230511" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmZlM2M5NTNhOTU3MTRhYjk5N2YwMmEzODY0NTVhZTI0L3NlYzpmZTNjOTUzYTk1NzE0YWI5OTdmMDJhMzg2NDU1YWUyNF8xL2ZyYWc6ZTc5NWZhZTg4NDZmNGIzZGFlZThkZTIwNjIxZmI0MTAvdGV4dHJlZ2lvbjplNzk1ZmFlODg0NmY0YjNkYWVlOGRlMjA2MjFmYjQxMF8xNjE2_452cfdb1-61e4-477b-8373-4c67d8755888">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="iab1696d2ac69401598d18b7b33e087c3_D20230511-20230511" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmZlM2M5NTNhOTU3MTRhYjk5N2YwMmEzODY0NTVhZTI0L3NlYzpmZTNjOTUzYTk1NzE0YWI5OTdmMDJhMzg2NDU1YWUyNF8xL2ZyYWc6ZTc5NWZhZTg4NDZmNGIzZGFlZThkZTIwNjIxZmI0MTAvdGV4dHJlZ2lvbjplNzk1ZmFlODg0NmY0YjNkYWVlOGRlMjA2MjFmYjQxMF8yNzQ4Nzc5MDcxMDcz_ad9bfdad-84ad-4349-9025-9a0e6a702d7d">May 11, 2023</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iab1696d2ac69401598d18b7b33e087c3_D20230511-20230511" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmZlM2M5NTNhOTU3MTRhYjk5N2YwMmEzODY0NTVhZTI0L3NlYzpmZTNjOTUzYTk1NzE0YWI5OTdmMDJhMzg2NDU1YWUyNF8xL2ZyYWc6ZTc5NWZhZTg4NDZmNGIzZGFlZThkZTIwNjIxZmI0MTAvdGV4dHJlZ2lvbjplNzk1ZmFlODg0NmY0YjNkYWVlOGRlMjA2MjFmYjQxMF8xNjE4_71fcaaf7-1f43-463d-9e23-7445c3e3b6bc">EIGER BIOPHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="iab1696d2ac69401598d18b7b33e087c3_D20230511-20230511" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmZlM2M5NTNhOTU3MTRhYjk5N2YwMmEzODY0NTVhZTI0L3NlYzpmZTNjOTUzYTk1NzE0YWI5OTdmMDJhMzg2NDU1YWUyNF8xL2ZyYWc6ZTc5NWZhZTg4NDZmNGIzZGFlZThkZTIwNjIxZmI0MTAvdGFibGU6NTJjNzkwODNhMjYyNDY0NmEzZWNjMzE5MjA5NWM3NjYvdGFibGVyYW5nZTo1MmM3OTA4M2EyNjI0NjQ2YTNlY2MzMTkyMDk1Yzc2Nl8wLTAtMS0xLTQ5Njc3_c93f7e18-3d82-4cae-9527-43040591680f">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="iab1696d2ac69401598d18b7b33e087c3_D20230511-20230511" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZlM2M5NTNhOTU3MTRhYjk5N2YwMmEzODY0NTVhZTI0L3NlYzpmZTNjOTUzYTk1NzE0YWI5OTdmMDJhMzg2NDU1YWUyNF8xL2ZyYWc6ZTc5NWZhZTg4NDZmNGIzZGFlZThkZTIwNjIxZmI0MTAvdGFibGU6NTJjNzkwODNhMjYyNDY0NmEzZWNjMzE5MjA5NWM3NjYvdGFibGVyYW5nZTo1MmM3OTA4M2EyNjI0NjQ2YTNlY2MzMTkyMDk1Yzc2Nl8wLTEtMS0xLTQ5Njc3_254b4d67-8819-4ed7-94a5-21a4010c13c9">001-36183</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="iab1696d2ac69401598d18b7b33e087c3_D20230511-20230511" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZlM2M5NTNhOTU3MTRhYjk5N2YwMmEzODY0NTVhZTI0L3NlYzpmZTNjOTUzYTk1NzE0YWI5OTdmMDJhMzg2NDU1YWUyNF8xL2ZyYWc6ZTc5NWZhZTg4NDZmNGIzZGFlZThkZTIwNjIxZmI0MTAvdGFibGU6NTJjNzkwODNhMjYyNDY0NmEzZWNjMzE5MjA5NWM3NjYvdGFibGVyYW5nZTo1MmM3OTA4M2EyNjI0NjQ2YTNlY2MzMTkyMDk1Yzc2Nl8wLTItMS0xLTQ5Njc3_bd5c9309-dcdf-4a97-aabf-a2a7aa9500b4">33-0971591</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eiger BioPharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iab1696d2ac69401598d18b7b33e087c3_D20230511-20230511" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmZlM2M5NTNhOTU3MTRhYjk5N2YwMmEzODY0NTVhZTI0L3NlYzpmZTNjOTUzYTk1NzE0YWI5OTdmMDJhMzg2NDU1YWUyNF8xL2ZyYWc6ZTc5NWZhZTg4NDZmNGIzZGFlZThkZTIwNjIxZmI0MTAvdGV4dHJlZ2lvbjplNzk1ZmFlODg0NmY0YjNkYWVlOGRlMjA2MjFmYjQxMF8xNjE1_bca3d503-b5bb-455f-b688-31b772295de9">2155 Park Blvd.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iab1696d2ac69401598d18b7b33e087c3_D20230511-20230511" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmZlM2M5NTNhOTU3MTRhYjk5N2YwMmEzODY0NTVhZTI0L3NlYzpmZTNjOTUzYTk1NzE0YWI5OTdmMDJhMzg2NDU1YWUyNF8xL2ZyYWc6ZTc5NWZhZTg4NDZmNGIzZGFlZThkZTIwNjIxZmI0MTAvdGV4dHJlZ2lvbjplNzk1ZmFlODg0NmY0YjNkYWVlOGRlMjA2MjFmYjQxMF8xNjEz_718019de-863f-4e40-9f9f-56c5098fa8b1">Palo Alto</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="iab1696d2ac69401598d18b7b33e087c3_D20230511-20230511" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmZlM2M5NTNhOTU3MTRhYjk5N2YwMmEzODY0NTVhZTI0L3NlYzpmZTNjOTUzYTk1NzE0YWI5OTdmMDJhMzg2NDU1YWUyNF8xL2ZyYWc6ZTc5NWZhZTg4NDZmNGIzZGFlZThkZTIwNjIxZmI0MTAvdGV4dHJlZ2lvbjplNzk1ZmFlODg0NmY0YjNkYWVlOGRlMjA2MjFmYjQxMF8xNjE0_e42de855-7539-4341-92ac-09c07b5396dc">California</ix:nonNumeric>&#160;<ix:nonNumeric contextRef="iab1696d2ac69401598d18b7b33e087c3_D20230511-20230511" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmZlM2M5NTNhOTU3MTRhYjk5N2YwMmEzODY0NTVhZTI0L3NlYzpmZTNjOTUzYTk1NzE0YWI5OTdmMDJhMzg2NDU1YWUyNF8xL2ZyYWc6ZTc5NWZhZTg4NDZmNGIzZGFlZThkZTIwNjIxZmI0MTAvdGV4dHJlZ2lvbjplNzk1ZmFlODg0NmY0YjNkYWVlOGRlMjA2MjFmYjQxMF81OTY_4a2fffd8-6e5e-4ac3-98f9-1e0ecd73982b">94306</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="iab1696d2ac69401598d18b7b33e087c3_D20230511-20230511" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmZlM2M5NTNhOTU3MTRhYjk5N2YwMmEzODY0NTVhZTI0L3NlYzpmZTNjOTUzYTk1NzE0YWI5OTdmMDJhMzg2NDU1YWUyNF8xL2ZyYWc6ZTc5NWZhZTg4NDZmNGIzZGFlZThkZTIwNjIxZmI0MTAvdGV4dHJlZ2lvbjplNzk1ZmFlODg0NmY0YjNkYWVlOGRlMjA2MjFmYjQxMF8xNjEw_96d95708-ee8d-4d08-b79c-118f8e08f4b0">650</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="iab1696d2ac69401598d18b7b33e087c3_D20230511-20230511" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZlM2M5NTNhOTU3MTRhYjk5N2YwMmEzODY0NTVhZTI0L3NlYzpmZTNjOTUzYTk1NzE0YWI5OTdmMDJhMzg2NDU1YWUyNF8xL2ZyYWc6ZTc5NWZhZTg4NDZmNGIzZGFlZThkZTIwNjIxZmI0MTAvdGV4dHJlZ2lvbjplNzk1ZmFlODg0NmY0YjNkYWVlOGRlMjA2MjFmYjQxMF8xNjEx_30c1bf03-31a9-4fa9-b9bc-3cc8461c9b7b">272-6138</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="iab1696d2ac69401598d18b7b33e087c3_D20230511-20230511" name="dei:WrittenCommunications" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmZlM2M5NTNhOTU3MTRhYjk5N2YwMmEzODY0NTVhZTI0L3NlYzpmZTNjOTUzYTk1NzE0YWI5OTdmMDJhMzg2NDU1YWUyNF8xL2ZyYWc6ZTc5NWZhZTg4NDZmNGIzZGFlZThkZTIwNjIxZmI0MTAvdGFibGU6YTBjMzBhY2I3YWMwNDIyNTk0MmZiNzg4MThjZDA0NzQvdGFibGVyYW5nZTphMGMzMGFjYjdhYzA0MjI1OTQyZmI3ODgxOGNkMDQ3NF8wLTAtMS0xLTQ5Njc3_65ce756b-ad32-43f3-b7c5-357bf00b9562">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="iab1696d2ac69401598d18b7b33e087c3_D20230511-20230511" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmZlM2M5NTNhOTU3MTRhYjk5N2YwMmEzODY0NTVhZTI0L3NlYzpmZTNjOTUzYTk1NzE0YWI5OTdmMDJhMzg2NDU1YWUyNF8xL2ZyYWc6ZTc5NWZhZTg4NDZmNGIzZGFlZThkZTIwNjIxZmI0MTAvdGFibGU6YTBjMzBhY2I3YWMwNDIyNTk0MmZiNzg4MThjZDA0NzQvdGFibGVyYW5nZTphMGMzMGFjYjdhYzA0MjI1OTQyZmI3ODgxOGNkMDQ3NF8yLTAtMS0xLTQ5Njc3_ac970fa7-d585-49e7-9625-ca8c49c99565">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="iab1696d2ac69401598d18b7b33e087c3_D20230511-20230511" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmZlM2M5NTNhOTU3MTRhYjk5N2YwMmEzODY0NTVhZTI0L3NlYzpmZTNjOTUzYTk1NzE0YWI5OTdmMDJhMzg2NDU1YWUyNF8xL2ZyYWc6ZTc5NWZhZTg4NDZmNGIzZGFlZThkZTIwNjIxZmI0MTAvdGFibGU6YTBjMzBhY2I3YWMwNDIyNTk0MmZiNzg4MThjZDA0NzQvdGFibGVyYW5nZTphMGMzMGFjYjdhYzA0MjI1OTQyZmI3ODgxOGNkMDQ3NF80LTAtMS0xLTQ5Njc3_b5dd956f-2ed9-488c-a80a-9f45c02250b7">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="iab1696d2ac69401598d18b7b33e087c3_D20230511-20230511" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmZlM2M5NTNhOTU3MTRhYjk5N2YwMmEzODY0NTVhZTI0L3NlYzpmZTNjOTUzYTk1NzE0YWI5OTdmMDJhMzg2NDU1YWUyNF8xL2ZyYWc6ZTc5NWZhZTg4NDZmNGIzZGFlZThkZTIwNjIxZmI0MTAvdGFibGU6YTBjMzBhY2I3YWMwNDIyNTk0MmZiNzg4MThjZDA0NzQvdGFibGVyYW5nZTphMGMzMGFjYjdhYzA0MjI1OTQyZmI3ODgxOGNkMDQ3NF82LTAtMS0xLTQ5Njc3_1fdd7b08-459e-48ae-9fee-65be4e12cc7d">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:31.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="iab1696d2ac69401598d18b7b33e087c3_D20230511-20230511" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmZlM2M5NTNhOTU3MTRhYjk5N2YwMmEzODY0NTVhZTI0L3NlYzpmZTNjOTUzYTk1NzE0YWI5OTdmMDJhMzg2NDU1YWUyNF8xL2ZyYWc6ZTc5NWZhZTg4NDZmNGIzZGFlZThkZTIwNjIxZmI0MTAvdGFibGU6NzAyNGU2MWY4OTc1NDA0NTg4ZjZjZmI5ZGMzOGI2OGMvdGFibGVyYW5nZTo3MDI0ZTYxZjg5NzU0MDQ1ODhmNmNmYjlkYzM4YjY4Y18xLTAtMS0xLTQ5Njc3_0f06b13b-f476-44b6-bdf7-4ee710ef5cf5">Common Stock, par value $0.001</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="iab1696d2ac69401598d18b7b33e087c3_D20230511-20230511" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmZlM2M5NTNhOTU3MTRhYjk5N2YwMmEzODY0NTVhZTI0L3NlYzpmZTNjOTUzYTk1NzE0YWI5OTdmMDJhMzg2NDU1YWUyNF8xL2ZyYWc6ZTc5NWZhZTg4NDZmNGIzZGFlZThkZTIwNjIxZmI0MTAvdGFibGU6NzAyNGU2MWY4OTc1NDA0NTg4ZjZjZmI5ZGMzOGI2OGMvdGFibGVyYW5nZTo3MDI0ZTYxZjg5NzU0MDQ1ODhmNmNmYjlkYzM4YjY4Y18xLTItMS0xLTQ5Njc3_c0ca692f-dc12-4c6c-879d-7f5392a1f839">EIGR</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="iab1696d2ac69401598d18b7b33e087c3_D20230511-20230511" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmZlM2M5NTNhOTU3MTRhYjk5N2YwMmEzODY0NTVhZTI0L3NlYzpmZTNjOTUzYTk1NzE0YWI5OTdmMDJhMzg2NDU1YWUyNF8xL2ZyYWc6ZTc5NWZhZTg4NDZmNGIzZGFlZThkZTIwNjIxZmI0MTAvdGFibGU6NzAyNGU2MWY4OTc1NDA0NTg4ZjZjZmI5ZGMzOGI2OGMvdGFibGVyYW5nZTo3MDI0ZTYxZjg5NzU0MDQ1ODhmNmNmYjlkYzM4YjY4Y18xLTQtMS0xLTQ5Njc3_3efadac5-cd1e-4aeb-abaf-d8bb0b21ee9e">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iab1696d2ac69401598d18b7b33e087c3_D20230511-20230511" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmZlM2M5NTNhOTU3MTRhYjk5N2YwMmEzODY0NTVhZTI0L3NlYzpmZTNjOTUzYTk1NzE0YWI5OTdmMDJhMzg2NDU1YWUyNF8xL2ZyYWc6ZTc5NWZhZTg4NDZmNGIzZGFlZThkZTIwNjIxZmI0MTAvdGV4dHJlZ2lvbjplNzk1ZmFlODg0NmY0YjNkYWVlOGRlMjA2MjFmYjQxMF8xNjEy_41c1e691-8f8b-4036-b88e-3d5e8d44d327">o</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><span><br/></span></div></div></div><div id="ife3c953a95714ab997f02a386455ae24_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.08pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 11, 2023, Eiger BioPharmaceuticals, Inc. reported its financial results for the quarter ended March 31, 2023. A copy of the press release titled &#8220;Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update,&#8221; is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form&#160;8-K&#160;shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section&#160;11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form&#160;8-K&#160;shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Eiger BioPharmaceuticals, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div id="ife3c953a95714ab997f02a386455ae24_10"></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements and Exhibits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) Exhibits.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.385%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">No.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="eigr-2023_mayx11xexx991.htm">Press release, dated May </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="eigr-2023_mayx11xexx991.htm">11</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="eigr-2023_mayx11xexx991.htm">, 2023, titled &#8220;Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="eigr-2023_mayx11xexx991.htm">&#8221;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><span><br/></span></div></div></div><div id="ife3c953a95714ab997f02a386455ae24_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.08pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Eiger BioPharmaceuticals, Inc.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Dated: May 11, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">/s/ David Apelian</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">David Apelian<br/>Interim Chief Executive Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "eigr-20230511.htm", "description": "8-K", "secsgml_size_bytes": 35922}]
{"company-data": {"conformed-name": "Eiger BioPharmaceuticals, Inc.", "cik": "0001305253", "assigned-sic": "2836", "irs-number": "361004130", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-36183", "film-number": "23911130"}, "business-address": {"street1": "2155 PARK BOULEVARD", "city": "PALO ALTO", "state": "CA", "zip": "94306", "phone": "650-279-9845"}, "mail-address": {"street1": "2155 PARK BOULEVARD", "city": "PALO ALTO", "state": "CA", "zip": "94306"}, "former-company": {"former-conformed-name": "Celladon Corp", "date-changed": "20041005"}}
eigr-20230511
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________________________________
FORM
8-K
_________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 11, 2023
_________________________________________________
EIGER BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
_________________________________________________
Delaware
001-36183
33-0971591
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
Eiger BioPharmaceuticals, Inc.
2155 Park Blvd.
Palo Alto
,
California
94306
(Address of principal executive offices, including zip code)
(
650
)
272-6138
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
_________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common Stock, par value $0.001
EIGR
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 2.02.
Results of Operations and Financial Condition.
On May 11, 2023, Eiger BioPharmaceuticals, Inc. reported its financial results for the quarter ended March 31, 2023. A copy of the press release titled "Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update," is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference.
The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Eiger BioPharmaceuticals, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No.
Description
99.1
Press release, dated May
11
, 2023, titled "Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
"
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Eiger BioPharmaceuticals, Inc.
Dated: May 11, 2023
By:
/s/ David Apelian
David Apelian
Interim Chief Executive Officer